In gynaecological malignancy, imaging is a critical investigation for disease detection, characterisation, staging, response assessment, post-treatment surveillance and identification of recurrence. Ultrasound, computerised tomography, magnetic resonance imaging and positron emission tomography are all useful and the appropriate imaging modality must be correctly selected to best inform the clinical questions. This chapter details the guidelines for the use of imaging at diagnosis and initial treatment, dealing with each of the following rare gynaecological tumour categories: cystic ovarian (borderline serous and mucinous, invasive mucinous, low grade serous, pseudomyxoma peritonei), solid ovarian (dysgerminomas, granulosa cell, Sertoli-Leydig, fibrothecomas and neuroendocrine), uterine (leiomyosarcoma, rhabdomyosarcoma, endometrial stromal cell sarcoma, clear cell and mucinous), cervical (non-HPV associated, adenoma malignum, small cell/neuroendocrine), vulval (melanomas and sarcomas) and trophoblastic. It then describes special considerations when imaging pregnant women or a paediatric age group. Finally, the role of imaging for surveillance and monitoring is discussed. Future directions in imaging, particularly with regard to the use of quantitative imaging biomarkers and the potential of artificial intelligence in image analysis and interpretation, are acknowledged.